Find, compare & contact
Rheinanthrone
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Rheinanthrone API 480-09-1?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Rheinanthrone. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Rheinanthrone
- Synonyms:
- Cas Number:
- 480-09-1
- DrugBank number:
- DB13175
- Unique Ingredient Identifier:
- 0YQK3WBH32
General Description:
Rheinanthrone, identified by CAS number 480-09-1, is a notable compound with significant therapeutic applications. Rheinanthrone is the active metabolite of senna glycoside known for its laxative effect . It is commonly produced by plants of the Rheum species .
Indications:
This drug is primarily indicated for: No approved indication. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Metabolism:
Rheinanthrone undergoes metabolic processing primarily in: Once in systemic circulation about 2.6% of rheinanthrone is metabolized to rhein as well as sennidins A and B via oxidation . This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.
Absorption:
The absorption characteristics of Rheinanthrone are crucial for its therapeutic efficacy: About 10% of rheinanthrone is absorbed from the gut . The drug's ability to rapidly penetrate into cells ensures quick onset of action.
Route of Elimination:
The elimination of Rheinanthrone from the body primarily occurs through: 2.8% of rheinanthrone is excreted in urine and 95% is excreted in feces . Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.
Pharmacodynamics:
Rheinanthrone exerts its therapeutic effects through: Rheinanthrone stimulates peristalsis and increases fecal water content to increase the movement of feces through the large intestine . The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.
Mechanism of Action:
Rheinanthrone functions by: Rheinanthrone appears to increase macrophage expression of cyclooxygenase 2 (COX2) which increases production of prostaglandin E2 (PGE2) . This increase in PGE2 is associated with a subsequent decrease in aquaporin 3 expression. The decreased expression of aquaporin 3 likely restricts reabsorption of water in the large intestine resulting in the laxative effect of rheinanthrone. Rheinanthrone also appears to stimulate peristalsis in the large intestine dependent on contact with the mucosal epithelium . This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Classification:
Rheinanthrone belongs to the class of organic compounds known as anthracenecarboxylic acids. These are organic compounds containing a carboxylic acid group attached to an anthracene ring system, classified under the direct parent group Anthracenecarboxylic acids. This compound is a part of the Organic compounds, falling under the Benzenoids superclass, and categorized within the Anthracenes class, specifically within the Anthracenecarboxylic acids and derivatives subclass.
Experimental Properties:
Further physical and chemical characteristics of Rheinanthrone include:
- Melting Point: 250-280
Rheinanthrone is a type of Antimetabolites
Antimetabolites are a prominent category of pharmaceutical active pharmaceutical ingredients (APIs) utilized in the treatment of various diseases, particularly cancer. These compounds are structurally similar to naturally occurring metabolites essential for cellular processes such as DNA and RNA synthesis. By mimicking these metabolites, antimetabolites interfere with the normal functioning of cellular pathways, leading to inhibition of cancer cell growth and proliferation.
One of the widely used antimetabolites is methotrexate, a folic acid antagonist that inhibits the enzyme dihydrofolate reductase, disrupting the production of DNA and RNA. This disruption impedes the growth of rapidly dividing cancer cells. Another common antimetabolite is 5-fluorouracil (5-FU), which inhibits the enzyme thymidylate synthase, thereby interfering with DNA synthesis and inhibiting cancer cell proliferation.
Antimetabolites can be classified into several subcategories based on their mechanism of action and chemical structure. These include purine and pyrimidine analogs, folic acid antagonists, and pyrimidine synthesis inhibitors. Examples of antimetabolites in these subcategories include azathioprine, cytarabine, and gemcitabine.
Despite their effectiveness, antimetabolites can exhibit certain side effects due to their interference with normal cellular processes. These side effects may include gastrointestinal disturbances, myelosuppression (reduced production of blood cells), and hepatotoxicity.
In conclusion, antimetabolites are a vital category of pharmaceutical APIs used in the treatment of various diseases, especially cancer. By mimicking natural metabolites and disrupting crucial cellular processes, these compounds effectively inhibit cancer cell growth and proliferation. However, their usage should be carefully monitored due to potential side effects.
